Drug Trial Radar · NCT07549321
A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
144
Planned (sponsor's estimate)
Start
Mar 30, 2026
Primary completion
Mar 2031
Study completion Mar 2031
Sponsor
- Lead sponsor
- Renaissance Pharma Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 months, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Neuroblastoma is the most common type of solid cancer found outside the brain in young children. Generally, it affects children younger than 5 years old, with the average age when it is found being just 2 years. Most patients have 'high-risk' disease, with spread of the disease to different sites (metastases). This multinational study aims to find out how effective and safe the treatment of a monoclonal anti-GD2 antibody hu14.18K322A (daretabart) is when used together with chemotherapy to treat children and young people who have high-risk neuroblastoma.
Conditions
- High-Risk Neuroblastoma
Interventions
hu1418K322A + Temozolomide + IrinotecanDrug
21-day cycle for a maximum of 12 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (ORR)Time frame: Assessed at end of treatment (up to 12 months)
- Metastatic complete response rate (mCRR)Time frame: Assessed at end of treatment (up to 12 months)
Locations
20 sites in 7 countries. Site status is shown where the registry gives one.
University of California San Francisco (UCSF)
San Francisco, California · Recruiting
Children's Hospital Colorado Anschutz Medical
Aurora, Colorado · Recruiting
The University of Chicago
Chicago, Illinois · Recruiting
University of Minnesota Masonic Children's Hospital
Minneapolis, Minnesota · Recruiting
The Children's Hospital at Montefiore
The Bronx, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
University of Texas Southwestern
Dallas, Texas · Recruiting
The Hospital for Sick Children
Toronto, Ontario, Canada · Recruiting
Rigshospitalet
Copenhagen, Denmark · Recruiting
La Timone Children's Hospital
Marseille, France · Recruiting
Institut Curie
Paris, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
Charité - Universitätsmedizin Berlin
Berlin, Germany · Recruiting
University Hospital Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital Sant Joan de Deu
Barcelona, Spain · Recruiting
Hospital Infantil Universitario Niño Jesús
Madrid, Spain · Recruiting
Royal Victoria Infirmary
Newcastle upon Tyne, United Kingdom · Recruiting
Royal Marsden NHS Foundation Trust
Sutton, United Kingdom · Recruiting
Southampton Children's Hospital
Southampton, Hampshire, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.